CN113125760A - Composition for detecting N-terminal brain natriuretic peptide precursor, magnetic microsphere electrochemiluminescence immunoassay kit and detection method - Google Patents
Composition for detecting N-terminal brain natriuretic peptide precursor, magnetic microsphere electrochemiluminescence immunoassay kit and detection method Download PDFInfo
- Publication number
- CN113125760A CN113125760A CN202110407489.4A CN202110407489A CN113125760A CN 113125760 A CN113125760 A CN 113125760A CN 202110407489 A CN202110407489 A CN 202110407489A CN 113125760 A CN113125760 A CN 113125760A
- Authority
- CN
- China
- Prior art keywords
- probnp
- reagent
- value
- buffer solution
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 title claims abstract description 25
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 title claims abstract description 25
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 title claims abstract description 25
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 title claims abstract description 25
- 239000002243 precursor Substances 0.000 title claims abstract description 25
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 title claims description 13
- 238000001514 detection method Methods 0.000 title abstract description 22
- 102400001263 NT-proBNP Human genes 0.000 claims abstract description 105
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229910052707 ruthenium Inorganic materials 0.000 claims abstract description 33
- 238000006243 chemical reaction Methods 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000004020 luminiscence type Methods 0.000 claims abstract description 13
- 101800001904 NT-proBNP Proteins 0.000 claims description 104
- 239000003153 chemical reaction reagent Substances 0.000 claims description 50
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 33
- 238000004140 cleaning Methods 0.000 claims description 30
- 108010090804 Streptavidin Proteins 0.000 claims description 25
- 229960002685 biotin Drugs 0.000 claims description 24
- 235000020958 biotin Nutrition 0.000 claims description 24
- 239000011616 biotin Substances 0.000 claims description 24
- 239000008055 phosphate buffer solution Substances 0.000 claims description 18
- 239000007853 buffer solution Substances 0.000 claims description 17
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 16
- IWSZDQRGNFLMJS-UHFFFAOYSA-N 2-(dibutylamino)ethanol Chemical compound CCCCN(CCO)CCCC IWSZDQRGNFLMJS-UHFFFAOYSA-N 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000002372 labelling Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 abstract description 14
- 239000003550 marker Substances 0.000 abstract description 6
- 238000003018 immunoassay Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 229910021645 metal ion Inorganic materials 0.000 abstract description 3
- WCYJXDMUQGVQQS-UHFFFAOYSA-N pyridine;ruthenium Chemical compound [Ru].C1=CC=NC=C1 WCYJXDMUQGVQQS-UHFFFAOYSA-N 0.000 abstract description 3
- 238000000835 electrochemical detection Methods 0.000 abstract description 2
- 238000002796 luminescence method Methods 0.000 abstract description 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 26
- 239000006249 magnetic particle Substances 0.000 description 11
- 238000011033 desalting Methods 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 229910000831 Steel Inorganic materials 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000010959 steel Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 206010024119 Left ventricular failure Diseases 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- -1 succinamide ruthenium Chemical compound 0.000 description 2
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 102100036836 Natriuretic peptides B Human genes 0.000 description 1
- 101710187802 Natriuretic peptides B Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000007170 intrinsic cardiomyopathy Diseases 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The invention relates to the field of electrochemical detection, in particular to a composition for detecting an N-terminal brain natriuretic peptide precursor (NT-proBNP), application thereof, a magnetic microsphere electrochemical luminescence immunoassay kit and a detection method. The method adopted by the invention is an electrochemical luminescence method, and the ruthenium pyridine adopted as the chemiluminescent marker has obvious advantages, which are mainly shown in that: the sensitivity is better, the stability is better, ruthenium is metal ion, the molecular weight is small, and the steric hindrance of the antibody is not influenced. Short production process, good repeatability and wide detection range. The electrochemical luminescence reaction is controllable, and the signal acquisition difficulty is reduced.
Description
Technical Field
The invention relates to the field of electrochemical detection, in particular to a composition for detecting an N-terminal brain natriuretic peptide precursor (NT-proBNP), application of the composition, a magnetic microsphere electrochemiluminescence immunoassay kit containing the composition, and a magnetic microsphere electrochemiluminescence immunoassay method based on the composition or the kit.
Background
proBNP is mainly secreted by ventricles, can be used for diagnosis and prognosis prediction, and is the most powerful predictor for independently predicting the death rate of patients with acute coronary syndrome within one year. The serum and plasma concentrations of NT-proBNP correlate with the prognosis of left ventricular dysfunction.
Left ventricular insufficiency commonly occurs with coronary heart disease, arterial hypertension, valvular heart disease, and primary cardiomyopathy. If left ventricular insufficiency is not treated in time and progresses further, the patient's mortality rate increases. The level of NT-proBNP increased with increasing progression, reflecting the severity of the cardiac injury. The high sensitivity of NT-proBNP also makes it possible to monitor mild cardiac dysfunction in asymptomatic patients suffering from organic heart disease. In the past, the diagnosis of left ventricular insufficiency has been performed using clinical information and imaging methods, and the significance of natriuretic peptides in controlling the function of the cardiovascular system has been demonstrated.
In addition, NT-proBNP is suitable for the evaluation of revascularization and thus aids in the establishment of individual recovery procedures. NT-proBNP may also reflect cardiac function and indicate an increased risk in patients prepared for intervention with cardiotoxic drugs or agents that cause fluid retention or volume overload (e.g., COX-2 inhibitors, non-steroidal anti-inflammatory drugs).
To date, the methods for detecting NT-proBNP in human serum are mainly: enzyme linked immunosorbent assay (ELISA) and enzymatic magnetic particle chemiluminescence. The method adopted by the invention is an electrochemical luminescence method, and the method adopting the terpyridyl ruthenium as the chemiluminescent marker has obvious advantages, which are mainly shown in that: the sensitivity is better, the stability is better, the terpyridyl ruthenium is metal ion, the molecular weight is small, and the steric hindrance of the antibody is not influenced. Short production process, wide detection range and good repeatability. The electrochemical luminescence reaction is controllable, and the signal acquisition difficulty is reduced.
Disclosure of Invention
The invention provides a composition for detecting an N-terminal brain natriuretic peptide precursor (NT-proBNP), application thereof, a magnetic microsphere electrochemiluminescence immunoassay kit and a detection method, and has the advantages of high production efficiency, short detection time, suitability for full-automatic detection, higher sensitivity, wide linear range and the like.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a composition for detecting N-terminal brain natriuretic peptide precursor (NT-proBNP), which comprises an NT-proBNP reagent Ra, an NT-proBNP reagent Rb and streptavidin superparamagnetic microspheres;
the NT-proBNP reagent Ra comprises an anti-NT-proBNP monoclonal antibody containing a biotin label;
the NT-proBNP reagent Rb comprises an anti-NT-proBNP monoclonal antibody marked by terpyridyl ruthenium;
the streptavidin superparamagnetic microspheres comprise superparamagnetic microspheres with streptavidin coated on the surfaces.
In some embodiments of the invention, the superparamagnetic microspheres have a particle size of 1.5 to 5.0 μm.
In some embodiments of the invention, the amount of the biotin molecular marker on the surface of each antibody molecule in the NT-proBNP reagent Ra is 2-5; in the NT-proBNP reagent Rb, the labeling quantity of ruthenium molecules on the surface of each antibody molecule is 2-10.
In some embodiments of the present invention, the NT-proBNP reagent Ra is prepared by the following steps: mixing the NT-proBNP resisting monoclonal antibody with biotin in the presence of a buffer solution to prepare the NT-proBNP reagent Ra; the buffer solution comprises a phosphate buffer solution with the pH value of 7.4-7.8 and the pH value of 20 mM-200 mM or a tris (hydroxymethyl) aminomethane buffer solution with the pH value of 7.4-7.8 and the pH value of 20 mM-200 mM.
In some embodiments of the present invention, the NT-proBNP reagent Ra is prepared by the following steps: 2.0mg of an antibody for labeling an N-terminal brain natriuretic peptide precursor (NT-proBNP) of biotin was taken, the buffer was changed to a phosphate buffer (pH 7.8) using a desalting column PD10, the antibody was concentrated using an ultrafiltration tube and adjusted to a concentration of 2.0mg/mL, 80 μ g of biotin (dissolved in DMF) was added thereto, the mixture was mixed and reacted for 30 minutes, and unlabeled biotin was removed using a desalting column PD 10. An N-terminal pro-brain natriuretic peptide (NT-proBNP) antibody labeled with biotin was diluted to 1mg/L with a phosphate buffer solution (pH 7.4) containing 1% bovine serum albumin as an NT-proBNP agent Ra.
In some embodiments of the invention, the NT-proBNP agent Rb is prepared by the following steps: mixing an anti-NT-proBNP monoclonal antibody with terpyridyl ruthenium in the presence of a buffer solution to prepare the NT-proBNP reagent Rb; the buffer solution comprises a phosphate buffer solution with the pH value of 7.4-7.8 and the pH value of 20 mM-200 mM or a tris (hydroxymethyl) aminomethane buffer solution with the pH value of 7.4-7.8 and the pH value of 20 mM-200 mM.
In some embodiments of the invention, the NT-proBNP agent Rb is prepared by the following steps: 2.0mg of an N-terminal brain natriuretic peptide precursor (NT-proBNP) antibody for labeling ruthenium terpyridyl was taken, the buffer was changed to a phosphate buffer (pH 7.8) using a desalting column PD10, the mixture was concentrated using an ultrafiltration tube and adjusted to a concentration of 2.0mg/mL, 80 μ g of succinamide ruthenium terpyridyl (dissolved in DMF) was added thereto, the mixture was mixed and reacted for 30 minutes, and unlabeled ruthenium was removed using a desalting column PD 10. An N-terminal brain natriuretic peptide precursor (NT-proBNP) antibody labeled with ruthenium was diluted to 1mg/L with a phosphate buffer solution (pH 7.4) containing 1% bovine serum albumin as an NT-proBNP agent Rb.
In some embodiments of the invention, the compositions provided herein further comprise a taggant and/or a cleaning solution; the cleaning solution comprises tripropylamine with the concentration of 150-200 mmol/L and phosphate buffer solution with the concentration of 200-400 mmol/L; or dibutylethanolamine with the concentration of 80-100 mmol/L and phosphate buffer solution with the concentration of 200-400 mmol/L.
In some embodiments of the present invention, the cleaning solution includes, but is not limited to, a tripropylamine cleaning solution, a dibutylethanolamine cleaning solution, a pipeline cleaning solution.
In some more specific embodiments of the present invention, the cleaning solution comprises tripropylamine at a concentration of 180mmol/L and a phosphate buffer at a concentration of 300 mmol/L; or dibutylethanolamine at a concentration of 90mmol/L and phosphate buffer at a concentration of 300 mmol/L.
In some embodiments of the invention, the volume ratio of the NT-proBNP reagent Ra, the NT-proBNP reagent Rb to the streptavidin superparamagnetic microspheres is (50-80): (50-80): (20-40).
On the basis of the research, the invention also provides application of the composition in preparing a magnetic microsphere electrochemiluminescence immunoassay kit of the N-terminal brain natriuretic peptide precursor (NT-proBNP).
The invention also provides a magnetic microsphere electrochemiluminescence immunoassay kit of the N-terminal brain natriuretic peptide precursor (NT-proBNP), which comprises the composition and a reagent acceptable for detection.
The invention also provides a magnetic microsphere electrochemiluminescence immunoassay method of N-terminal brain natriuretic peptide precursor (NT-proBNP), which is based on the composition or the kit and comprises the following steps:
step 1: taking a sample, sequentially adding an NT-proBNP reagent Ra and an NT-proBNP reagent Rb, incubating for 8-12 min at 37 ℃, finally adding streptavidin superparamagnetic microspheres, and incubating for 8-12 min at 37 ℃ to obtain a reaction solution; wherein the volume ratio of the sample, the NT-proBNP reagent Ra, the NT-proBNP reagent Rb to the streptavidin superparamagnetic microspheres is 15: (50-80): (50-80): (20-40);
step 2: adsorbing the reaction solution by using a magnet;
and step 3: taking a cleaning solution, cleaning the ruthenium-labeled antibody and the sample which are not bonded to the superparamagnetic microspheres, electrifying, and enabling the terpyridyl ruthenium to emit light under the condition of the presence of the cleaning solution;
and 4, step 4: and recording the luminescence value, establishing a standard curve, and obtaining the concentration of NT-proBNP in the sample according to the established standard curve.
In some embodiments of the invention, the incubation is at 37 ℃ for 9 min.
In some embodiments of the present invention, the detection method specifically comprises:
step 1: adding 15 μ l of sample into a reaction tube, sequentially adding 80 μ l of NT-proBNP reagent Ra and 75 μ l of NT-proBNP reagent Rb, incubating at 37 ℃ for 9min, finally adding 30 μ l of streptavidin superparamagnetic microspheres, and incubating at 37 ℃ for 9 min;
step 2: sucking the reaction tube after the incubation reaction into an electrochemical flow cell through a liquid absorption steel needle, and adsorbing the reaction tube by a magnet of the flow cell;
and step 3: and (3) sucking a cleaning solution (tripropylamine or DBAE) by a liquid suction steel needle, cleaning the ruthenium-labeled antibody which is not bound to the superparamagnetic microspheres and the sample, electrifying the flow cell, and emitting light by the terpyridyl ruthenium under the condition that the tripropylamine or DBAE exists.
And 4, step 4: recording the luminous value by the photomultiplier, establishing a standard curve, and calculating the concentration of NT-proBNP in the sample according to the established standard curve.
The magnetic particles can be used as carriers of biological macromolecules, the antibody-coated magnetic particles are called immune magnetic particles, and the immune magnetic particles have the characteristics of antigen combination and magnetism, so that the immune magnetic particles have more advantages in the aspects of separating, purifying and concentrating target microorganisms, cells, biological macromolecules and the like from complex samples, and comprise rapidness, strong specificity, simple and convenient operation, wide application range and the like. The nanometer material is a new material which is rapidly developed after 90 years in the 20 th century, and the nanometer magnetic particles (the particle size is less than 10 nm-100 nm) are greatly different from the common magnetic particles in the aspects of magnetic structure and magnetism: the nano magnetic particles have more particles per unit volume and larger specific surface area; the magnetic material has superparamagnetism, and the magnetic interaction is weak; it can move directionally under the action of external magnetic field to separate, concentrate or purify some special components. The magnetic particle chemiluminescence method established by the invention has the advantages of high sensitivity, strong specificity, accuracy, rapidness, short detection time and higher accuracy and repeatability of a detection result.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.
FIG. 1 shows the results of a straight line fit of the diluted concentration to the measured concentration in the reaction method of example 8- (1);
FIG. 2 shows the results of straight line fitting of the diluted concentration to the measured concentration in the reaction method of example 8- (2).
Detailed Description
The invention discloses a magnetic microsphere electrochemiluminescence immunoassay kit for detecting N-terminal brain natriuretic peptide precursor (NT-proBNP), which can be realized by appropriately improving process parameters by the technical personnel in the field by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The invention provides the following technical scheme: an NT-proBNP magnetic microsphere electrochemiluminescence kit, comprising: NT-proBNP reagent Ra, NT-proBNP reagent Rb, streptavidin superparamagnetic microspheres, calibration products, tripropylamine cleaning solution, dibutylethanolamine cleaning solution and pipeline cleaning solution.
The NT-proBNP magnetic microsphere electrochemiluminescence kit comprises an NT-proBNP reagent Ra, a biotin-labeled anti-NT-proBNP monoclonal antibody, wherein the labeled amount of biotin molecules on the surface of each antibody molecule is 2-5, the buffer solution is 20 mM-200 mM phosphate buffer solution, the pH value is 7.4-7.8 or 20 mM-200 mM tris (hydroxymethyl) aminomethane buffer solution, and the pH value is 7.4-7.8. The NT-proBNP reagent Rb is an anti-NT-proBNP monoclonal antibody containing a terpyridyl ruthenium marker, the marking amount of ruthenium molecules on the surface of each antibody molecule is 2-10, the buffer solution is 20 mM-200 mM phosphate buffer solution, the pH value is 7.4-7.8 or 20 mM-200 mM tris buffer solution, and the pH value is 7.4-7.8.
The NT-proBNP magnetic microsphere electrochemiluminescence kit comprises a magnetic microsphere coated with streptavidin, wherein the streptavidin superparamagnetic microsphere is coated with the streptavidin, the particle size of the magnetic microsphere is 1.5-5.0 micrometers, the magnetic particle coating buffer solution is 20 mM-200 mM phosphate buffer solution, the pH value is 7.4-7.8 or 20 mM-200 mM tris (hydroxymethyl) aminomethane buffer solution, and the pH value is 7.4-7.8.
The NT-proBNP magnetic microsphere electrochemiluminescence kit is characterized in that the NT-proBNP antibody marked by biotin is a monoclonal antibody;
the detection method of the NT-proBNP magnetic microsphere electrochemiluminescence kit comprises the following steps of (1) taking tripropylamine with the concentration of 180mmol/L and phosphate buffer with the concentration of 300mmol/L as a cleaning solution; or 90mmol/L dibutylethanolamine containing phosphate buffer solution with concentration of 300 mmol/L.
The invention provides a detection method of an NT-proBNP magnetic microsphere electrochemiluminescence kit, which comprises the following steps:
1) adding 15 μ l of sample into a reaction tube, sequentially adding 80 μ l of NT-proBNP reagent Ra and 75 μ l of NT-proBNP reagent Rb, incubating at 37 ℃ for 9min, finally adding 30 μ l of streptavidin superparamagnetic microspheres, and incubating at 37 ℃ for 9 min;
2) sucking the reaction tube after the incubation reaction into an electrochemical flow cell through a liquid absorption steel needle, and adsorbing the reaction tube by a magnet of the flow cell;
3) and (3) sucking a cleaning solution (tripropylamine or DBAE) by a liquid suction steel needle, cleaning the ruthenium-labeled antibody which is not bound to the superparamagnetic microspheres and the sample, electrifying the flow cell, and emitting light by the terpyridyl ruthenium under the condition that the tripropylamine or DBAE exists.
4) Recording the luminous value by the photomultiplier, establishing a standard curve, and calculating the concentration of NT-proBNP in the sample according to the established standard curve.
The streptavidin and the biotin have high-specificity binding capacity, and the streptavidin and the biotin-labeled high-purity antibody are specifically bound through non-covalent bonds, so that the streptavidin-labeled high-purity antibody has the effect of cascade amplification, and the reaction is highly specific. Therefore, the sensitivity is improved, non-specific interference is not increased, and the binding property is not affected by the high dilution of the reaction reagent, so that the non-specific action of the reaction reagent can be reduced to the maximum extent in practical application.
The invention combines the high specificity of antibody-antigen reaction with the high sensitivity of ruthenium terpyridyl luminescence, utilizes the photons generated by ruthenium terpyridyl under tripropylamine or DBAE to detect the product concentration, and has the characteristics of higher sensitivity, short reaction time, simple operation and high anti-interference performance.
The magnetic microsphere electrochemiluminescence immunoassay kit for detecting the N-terminal brain natriuretic peptide precursor (NT-proBNP) provided by the invention is commercially available in raw materials and reagents.
All components of the test kit of the present invention can be commercially obtained from biological or chemical reagents companies. The device used was a full-automatic chemiluminescence immunoassay analyzer (model UD90DT) manufactured by tek technologies ltd, yokyo.
The invention is further illustrated by the following examples:
example 1: preparation of Biotin-labeled N-terminal brain natriuretic peptide precursor (NT-proBNP) antibody and reagent Ra
An N-terminal brain natriuretic peptide precursor (NT-proBNP) antibody for labeling biotin is purchased from North Beijing edge Tianxin field science and technology Limited, with the product number of YT-NT-proBNP-002 and the clone number of 8A 4.
2.0mg of an antibody for labeling an N-terminal brain natriuretic peptide precursor (NT-proBNP) of biotin was taken, the buffer was changed to a phosphate buffer (pH 7.8) using a desalting column PD10, the antibody was concentrated using an ultrafiltration tube and adjusted to a concentration of 2.0mg/mL, 80 μ g of biotin (dissolved in DMF) was added thereto, the mixture was mixed and reacted for 30 minutes, and unlabeled biotin was removed using a desalting column PD 10. An N-terminal pro-brain natriuretic peptide (NT-proBNP) antibody labeled with biotin was diluted to 1mg/L with a phosphate buffer solution (pH 7.4) containing 1% bovine serum albumin as an NT-proBNP agent Ra. The number of biotin molecular markers on the surface of each antibody molecule is 2-3.
Example 2: preparation of ruthenium-labeled N-terminal brain natriuretic peptide precursor (NT-proBNP) antibody and Rb reagent
The N-terminal brain natriuretic peptide precursor (NT-proBNP) antibody for labeling biotin is purchased from Tianxin county science and technology ltd, Beijing, under the product number YT-NT-proBNP-003 and the clone number 7F 5.
2.0mg of an N-terminal brain natriuretic peptide precursor (NT-proBNP) antibody for labeling ruthenium terpyridyl was taken, the buffer was changed to a phosphate buffer (pH 7.8) using a desalting column PD10, the mixture was concentrated using an ultrafiltration tube and adjusted to a concentration of 2.0mg/mL, 80 μ g of succinamide ruthenium terpyridyl (dissolved in DMF) was added thereto, the mixture was mixed and reacted for 30 minutes, and unlabeled ruthenium was removed using a desalting column PD 10. An N-terminal brain natriuretic peptide precursor (NT-proBNP) antibody labeled with ruthenium was diluted to 1mg/L with a phosphate buffer solution (pH 7.4) containing 1% bovine serum albumin as an NT-proBNP agent Rb. The number of the ruthenium molecular markers on the surface of each antibody molecule is 5-6.
Example 3: preparation of the calibration articles
The antigen for preparing the calibration sample is purchased from Ji-shi limited of Tian Xin Beijing, and has a product number of YT-NT-proBNP-001. For recombinant expression of the protein.
The antigen was diluted to 140.0pg/mL and 2700pg/mL at the indicated concentrations using a phosphate buffer (pH 7.4) containing 1% bovine serum albumin. Used as a calibrator for establishing a standard curve.
Example 4: preparation of tripropylamine cleaning solution and dibutylethanolamine cleaning solution
300mmol/L phosphate buffer solution is prepared, tripropylamine is added to 180mmol/L, and the mixture is mixed and dissolved. As a tripropylamine cleaning solution.
Preparing 300mmol/L phosphate buffer solution, adding dibutyl ethanolamine to 90mmol/L, and mixing and dissolving. As a cleaning solution of dibutylethanolamine.
Example 5:
the N-terminal brain natriuretic peptide precursor (NT-proBNP) is determined by a sandwich method, and the detection method is as follows:
1) adding 15 μ l of sample into a reaction tube, sequentially adding 80 μ l of NT-proBNP reagent Ra prepared in example 1 and 75 μ l of NT-proBNP reagent Rb prepared in example 2, incubating at 37 ℃ for 9min, finally adding 30 μ l of streptavidin magnetic microsphere (with particle size of 3.0 μm), and incubating at 37 ℃ for 9 min;
2) sucking the reaction tube after the incubation reaction into an electrochemical flow cell through a liquid absorption steel needle, and adsorbing the reaction tube by a magnet of the flow cell;
3) and (3) sucking a cleaning solution (tripropylamine) by a liquid suction steel needle, cleaning the ruthenium-labeled antibody which is not bound to the superparamagnetic microspheres and the sample, electrifying the flow cell, and emitting light by the terpyridyl ruthenium in the presence of the tripropylamine.
4) And recording the luminous value by using a photomultiplier, and calculating the concentration of NT-proBNP in the sample according to a standard curve established after the luminous value of the calibration object is corrected.
Example 6:
the N-terminal brain natriuretic peptide precursor (NT-proBNP) is determined by a sandwich method, and the detection method is as follows:
1) adding 15 μ l of sample into a reaction tube, sequentially adding 80 μ l of NT-proBNP reagent Ra prepared in example 1 and 75 μ l of NT-proBNP reagent Rb prepared in example 2, incubating at 37 ℃ for 9min, finally adding 30 μ l of streptavidin superparamagnetic microspheres (with particle size of 3.0 μm), and incubating at 37 ℃ for 9 min;
2) adding a streptavidin-coated superparamagnetic microsphere for incubation, and allowing the formed immune complex to be bound to the superparamagnetic microsphere through the interaction between biotin and streptavidin;
3) after incubation, absorbing the reaction mixture into a measuring cell, adsorbing the superparamagnetic microspheres onto an electrode through a magnet, absorbing the cleaning solution (dibutylethanolamine) by a liquid absorbing steel needle, and absorbing a mark Ru (bpy) which is not combined with the superparamagnetic microspheres3 2+After the antibody and the sample were washed, the flow cell was charged, and Ru (bpy) was performed in the presence of dibutylethanolamine3 2+And (4) emitting light.
4) And recording the luminous value by using a photomultiplier, and calculating the concentration of NT-proBNP in the sample according to a standard curve established after the luminous value of the calibration object is corrected.
Example 7: margin test
(1) The reaction method in example 5 was used, and the RLU value (relative luminescence value) of 20 measurements was obtained using the zero-concentration diluent as the sample, and the average (M) and Standard Deviation (SD) thereof were calculated to obtain M +2SD, and at the same time, samples of adjacent concentrations were repeatedly tested 2 times, and two-point regression fitting was performed according to the concentration-RLU between the zero-concentration diluent and the adjacent low-concentration samples to obtain a linear equation, and the RLU value of M +2SD was substituted into the above equation to obtain the corresponding concentration value, which was the margin.
TABLE 1
(2) The reaction method in example 6 was used, and a zero-concentration diluent was used as a sample to obtain RLU values (relative luminescence values) of 20 measurements, and the average (M) and Standard Deviation (SD) thereof were calculated to obtain M +2SD, and samples of adjacent concentrations were repeatedly tested 2 times, and two-point regression fitting was performed according to the concentration-RLU between the zero-concentration diluent and the adjacent low-concentration samples to obtain a linear equation, and the RLU values of M +2SD were substituted into the above equation to obtain the corresponding concentration value, which was the blank limit.
TABLE 2
Example 8: verification of linear range
(1) Using the reaction method of example 5, the high value sample near the upper limit of the linear range (35000pg/ml) was diluted to at least 5 concentrations in a proportion where the low value concentration sample was close to 10 pg/ml. And (3) repeatedly detecting the samples with each concentration for 2 times, calculating the average value of the samples to obtain the measured concentration, performing straight line fitting on the diluted concentration and the measured concentration by using a least square method, and calculating a linear correlation coefficient r, wherein r is not less than 0.99. The results of a straight line fit of the diluted concentrations to the measured concentrations are shown in figure 1.
TABLE 3
(2) The reaction method of example 6, wherein the high value sample near the upper limit of the linear range (35000pg/ml) is diluted to at least 5 concentrations in a proportion, wherein the low value concentration sample should be near 10 pg/ml. And (3) repeatedly detecting the samples with each concentration for 2 times, calculating the average value of the samples to obtain the measured concentration, performing straight line fitting on the diluted concentration and the measured concentration by using a least square method, and calculating a linear correlation coefficient r, wherein r is not less than 0.99. The results of a straight line fit of the diluted concentrations to the measured concentrations are shown in figure 1.
TABLE 4
Summary of the comparative kit conditions:
TABLE 5
| Examples 7 to 8 | Comparative example 1 | Comparative example 2 | |
| Methodology of | Electrochemiluminescence sandwich method | Enzymatic chemiluminescence method | Enzyme linked immunosorbent assay |
| Sensitivity of the probe | 5pg/ml | 20pg/ml | 10pg/ml |
| Linear range | 10-35000pg/ml | 20-30000pg/ml | 12.4-400pg/ml |
| Time of detection | 18 minutes | 20 minutes | 90 minutes |
| Antibody treatment | 60 minutes | Greater than 2 hours | Greater than 10 hours |
The electrochemical luminescence immunoassay technology has the advantages of high sensitivity, rapidness, accuracy, good repeatability, safety, no toxicity, no pollution and the like. Luminol, isoluminol and its derivatives are the first type of chemiluminescent species used, but their application to chemiluminescent immunoassays requires the use of catalysts and enhancers, which leads to an increase in background luminescence, thereby limiting the sensitivity of this technology and its application and development. The acridinium ester luminescent system is simple, does not need a catalyst and is placed in H2O2The acridinium ester can emit light in the solution without a catalytic process or an enhancer, so background light emission is reduced, sensitivity is improved, interference effect is small, but the acridinium ester is easy to hydrolyze, and the light emission of the acridinium ester is released rapidly. The peak value of luminescence is 0.4s, so in-situ sample injection is needed, and the requirement on equipment is high. The ruthenium terpyridyl is easy to be connected with protein, has small molecular weight, has small influence on the conformation of the connected antibody, and has good stability because the marker is metal ions and controllable luminescence because the luminescence is required under the condition of electrification. Therefore, the application of the electrochemical method in the detection of NT-proBNP can improve the sensitivity of the product, shorten the process marking time, improve the linear range and shorten the test time, and provides the basis for the clinical treatment of responding to the brain trauma in timeAccordingly.
The property of the electrochemiluminescence marker ruthenium pyridine is very stable, and the luminous efficiency of the electrochemiluminescence marker ruthenium pyridine is not influenced by factors such as temperature, pH and ionic strength. The signal value of the electrochemiluminescence reagent is reduced within 3 percent compared with that of a fresh reagent. The bottle opening period is three months, and the bottle can be stabilized at 2-8 ℃ for more than 15 months.
TABLE 6
| Light-emitting system | Horseradish enzyme-luminol | Alkaline phosphatase | Electrochemiluminescence |
| Time stamping | Greater than 24 hours | Greater than 24 hours | 60 minutes |
| Test time | 60 minutes | 30 minutes | 18 minutes |
| Expiration date of reagent | 12 months old | 12 months old | More than 15 months |
The electrochemical labeling reaction is rapid, and the whole reaction only needs half an hour. The marking efficiency reaches 70%. The proportion of the marks can be controlled by the feed ratio, and the productivity is improved by over 50 percent. Ruthenium has small molecular weight (800D), small steric hindrance and good antibody activity. An absorption peak at 455nm, the feed ratio can be controlled to control the batch-to-batch difference.
The steps show that the reaction mode of the sandwich method adopted by the invention utilizes the principle of magnetic microsphere electrochemistry to quantitatively detect the content of the N-terminal brain natriuretic peptide precursor (NT-proBNP) in the human serum or plasma sample, thereby ensuring the detection sensitivity. And is suitable for use in fully automatic equipment. The detection speed and the detection flux are increased, the detection efficiency is improved, and errors caused by manual operation are avoided.
Those of ordinary skill in the art will understand that: the discussion of any embodiment above is meant to be exemplary only, and is not intended to intimate that the scope of the disclosure, including the claims, is limited to those examples; within the idea of the invention, also technical features in the above embodiments or in different embodiments may be combined and there are many other variations of the different aspects of the invention as described above, which are not provided in detail for the sake of brevity. Therefore, any omissions, modifications, substitutions, improvements and the like that may be made without departing from the spirit and principles of the invention are intended to be included within the scope of the invention.
Claims (10)
1. A composition for detecting N-terminal brain natriuretic peptide precursor (NT-proBNP) is characterized by comprising an NT-proBNP reagent Ra, an NT-proBNP reagent Rb and a streptavidin superparamagnetic microsphere;
the NT-proBNP reagent Ra comprises an anti-NT-proBNP monoclonal antibody containing a biotin label;
the NT-proBNP reagent Rb comprises an anti-NT-proBNP monoclonal antibody marked by terpyridyl ruthenium;
the streptavidin superparamagnetic microspheres comprise superparamagnetic microspheres with streptavidin coated on the surfaces.
2. The composition of claim 1, wherein the superparamagnetic microspheres have a particle size of 1.5 to 5.0 μm.
3. The composition of claim 1, wherein the amount of biotin molecular markers per antibody molecule surface in the NT-proBNP agent Ra is 2 to 5; in the NT-proBNP reagent Rb, the labeling quantity of ruthenium molecules on the surface of each antibody molecule is 2-10.
4. The composition according to any one of claims 1 to 3, wherein the NT-proBNP agent Ra is prepared by: mixing the NT-proBNP resisting monoclonal antibody with biotin in the presence of a buffer solution to prepare the NT-proBNP reagent Ra; the buffer solution comprises a phosphate buffer solution with the pH value of 7.4-7.8 and the pH value of 20 mM-200 mM or a tris (hydroxymethyl) aminomethane buffer solution with the pH value of 7.4-7.8 and the pH value of 20 mM-200 mM.
5. The composition according to any one of claims 1 to 3, wherein NT-proBNP agent Rb is prepared by: mixing an anti-NT-proBNP monoclonal antibody with terpyridyl ruthenium in the presence of a buffer solution to prepare the NT-proBNP reagent Rb; the buffer solution comprises a phosphate buffer solution with the pH value of 7.4-7.8 and the pH value of 20 mM-200 mM or a tris (hydroxymethyl) aminomethane buffer solution with the pH value of 7.4-7.8 and the pH value of 20 mM-200 mM.
6. A composition according to any one of claims 1 to 3, further comprising a standard and/or a cleaning solution; the cleaning solution comprises tripropylamine with the concentration of 150-200 mmol/L and phosphate buffer solution with the concentration of 200-400 mmol/L; or dibutylethanolamine with the concentration of 80-100 mmol/L and phosphate buffer solution with the concentration of 200-400 mmol/L.
7. The composition of any one of claims 1 to 3, wherein the volume ratio of NT-proBNP agent Ra, NT-proBNP agent Rb to streptavidin superparamagnetic microspheres is (50-80): (50-80): (20-40).
8. Use of a composition according to any one of claims 1 to 7 for the preparation of a magnetic microsphere electrochemiluminescence immunoassay kit for N-terminal pro-brain natriuretic peptide (NT-proBNP).
9. A magnetic microsphere electrochemiluminescence immunoassay kit for N-terminal pro-brain natriuretic peptide (NT-proBNP), comprising the composition of any one of claims 1 to 7 and a detection-acceptable reagent.
A method for magnetic microsphere electrochemiluminescence immunoassay of N-terminal pro-brain natriuretic peptide (NT-proBNP) based on a composition according to any of claims 1 to 7 or a kit according to claim 9, comprising the steps of:
step 1: taking a sample, sequentially adding an NT-proBNP reagent Ra and an NT-proBNP reagent Rb, incubating for 8-12 min at 37 ℃, finally adding streptavidin superparamagnetic microspheres, and incubating for 8-12 min at 37 ℃ to obtain a reaction solution; wherein the volume ratio of the sample, the NT-proBNP reagent Ra, the NT-proBNP reagent Rb to the streptavidin superparamagnetic microspheres is 15: (50-80): (50-80): (20-40);
step 2: adsorbing the reaction solution by using a magnet;
and step 3: taking a cleaning solution, cleaning the ruthenium-labeled antibody and the sample which are not bonded to the superparamagnetic microspheres, electrifying, and enabling the terpyridyl ruthenium to emit light under the condition of the presence of the cleaning solution;
and 4, step 4: and recording the luminescence value, establishing a standard curve, and obtaining the concentration of NT-proBNP in the sample according to the established standard curve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110407489.4A CN113125760A (en) | 2021-04-15 | 2021-04-15 | Composition for detecting N-terminal brain natriuretic peptide precursor, magnetic microsphere electrochemiluminescence immunoassay kit and detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110407489.4A CN113125760A (en) | 2021-04-15 | 2021-04-15 | Composition for detecting N-terminal brain natriuretic peptide precursor, magnetic microsphere electrochemiluminescence immunoassay kit and detection method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113125760A true CN113125760A (en) | 2021-07-16 |
Family
ID=76776820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110407489.4A Pending CN113125760A (en) | 2021-04-15 | 2021-04-15 | Composition for detecting N-terminal brain natriuretic peptide precursor, magnetic microsphere electrochemiluminescence immunoassay kit and detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113125760A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112505334A (en) * | 2020-11-23 | 2021-03-16 | 厦门宝太生物科技有限公司 | NT-proBNP homogeneous phase chemiluminescence detection kit |
| CN114280311A (en) * | 2021-11-10 | 2022-04-05 | 宏葵生物（中国）股份有限公司 | Preparation method and detection application of nano-magnetic particle chemiluminescence detection kit for amino-terminal B-type natriuretic peptide precursor |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130273667A1 (en) * | 2012-04-16 | 2013-10-17 | Access Medical Systems, Ltd. | Wide range luminescent immunoassays |
| US20180292394A1 (en) * | 2016-04-11 | 2018-10-11 | Joshua Caine Soldo | Sample depletion and enrichment to improve the quality of diagnostic test results |
| CN111480081A (en) * | 2017-12-13 | 2020-07-31 | 豪夫迈·罗氏有限公司 | Circulating angiopoietin-2 (Ang-2) and insulin-like growth factor binding protein 7(IGFBP7) for prediction of stroke |
| CN111665237A (en) * | 2019-03-08 | 2020-09-15 | 上海索昕生物科技有限公司 | Homogeneous phase chemiluminescence detection method and application thereof |
| CN112649616A (en) * | 2020-12-30 | 2021-04-13 | 北京联众泰克科技有限公司 | Composition for detecting cardiac troponin I, application thereof, magnetic microsphere electrochemiluminescence immunoassay kit and detection method |
-
2021
- 2021-04-15 CN CN202110407489.4A patent/CN113125760A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130273667A1 (en) * | 2012-04-16 | 2013-10-17 | Access Medical Systems, Ltd. | Wide range luminescent immunoassays |
| US20180292394A1 (en) * | 2016-04-11 | 2018-10-11 | Joshua Caine Soldo | Sample depletion and enrichment to improve the quality of diagnostic test results |
| CN111480081A (en) * | 2017-12-13 | 2020-07-31 | 豪夫迈·罗氏有限公司 | Circulating angiopoietin-2 (Ang-2) and insulin-like growth factor binding protein 7(IGFBP7) for prediction of stroke |
| CN111665237A (en) * | 2019-03-08 | 2020-09-15 | 上海索昕生物科技有限公司 | Homogeneous phase chemiluminescence detection method and application thereof |
| CN112649616A (en) * | 2020-12-30 | 2021-04-13 | 北京联众泰克科技有限公司 | Composition for detecting cardiac troponin I, application thereof, magnetic microsphere electrochemiluminescence immunoassay kit and detection method |
Non-Patent Citations (2)
| Title |
|---|
| CONCETTA PRONTERA 等: "Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP" * |
| 魏雪梅 等: "N末端脑利钠肽前体电化学发光检测方法的建立" * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112505334A (en) * | 2020-11-23 | 2021-03-16 | 厦门宝太生物科技有限公司 | NT-proBNP homogeneous phase chemiluminescence detection kit |
| CN112505334B (en) * | 2020-11-23 | 2021-12-28 | 厦门宝太生物科技股份有限公司 | NT-proBNP homogeneous phase chemiluminescence detection kit |
| CN114280311A (en) * | 2021-11-10 | 2022-04-05 | 宏葵生物（中国）股份有限公司 | Preparation method and detection application of nano-magnetic particle chemiluminescence detection kit for amino-terminal B-type natriuretic peptide precursor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112649616A (en) | Composition for detecting cardiac troponin I, application thereof, magnetic microsphere electrochemiluminescence immunoassay kit and detection method | |
| CN109975557B (en) | IL-6/PCT combined detection time resolution detection kit and method | |
| US20210190778A1 (en) | Assay methods | |
| US11959912B2 (en) | Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof | |
| WO2021258618A1 (en) | Biological sample testing method and test kit | |
| CN113125760A (en) | Composition for detecting N-terminal brain natriuretic peptide precursor, magnetic microsphere electrochemiluminescence immunoassay kit and detection method | |
| CN111024956A (en) | Time-resolved fluorescence immunochromatography kit for detecting PTX3 | |
| CN110579609A (en) | AKR1B10 chemiluminescence quantitative detection kit and application thereof | |
| US20230333097A1 (en) | KIT FOR DETECTING ANTI-VINCULIN-IMMUNOGLOBULIN G (IgG) ANTIBODY | |
| CN110988368A (en) | Free thyroxine luminescence immunoassay kit and preparation method thereof | |
| CN111766390A (en) | Adiponectin chemiluminescence immunoassay kit | |
| CN112505322A (en) | Alzheimer disease marker p-Tau217 detection kit and manufacturing method thereof | |
| CN111007266A (en) | Chemiluminescence quantitative detection kit for detecting B-type natriuretic peptide in blood plasma | |
| CN113125761A (en) | Composition for procalcitonin detection, application of composition, magnetic microsphere electrochemiluminescence immunoassay kit and detection method | |
| CN117434274A (en) | Single interleukin 6 magnetic particle chemiluminescence kit and determination method thereof | |
| CN112798781A (en) | Composition for detecting human epididymis protein 4, application of composition, magnetic microsphere electrochemiluminescence immunoassay kit and detection method | |
| CN112834756A (en) | Composition for detecting interleukin 6, application of composition, magnetic microsphere electrochemiluminescence immunoassay kit and detection method | |
| CN114509569A (en) | Kit for detecting interleukin 6, detection method and application | |
| AU2015239040A1 (en) | Control means for implementing multiplex analysis methods | |
| US20210096075A1 (en) | Kit for quickly detecting cadmium content in sample | |
| CN109085343B (en) | Kit for determining anti-Jo-1 antibody and detection method | |
| CN111487409A (en) | Chemiluminescence detection kit for S100B protein and use method thereof | |
| CN113092789A (en) | Composition for myoglobin detection, application thereof, magnetic microsphere electrochemiluminescence immunoassay kit and detection method | |
| CN112816716A (en) | Composition for C peptide detection, application of composition, magnetic microsphere electrochemiluminescence immunoassay kit and detection method | |
| CN112816703A (en) | Composition for anti-mullerian hormone detection, application of composition, magnetic microsphere electrochemiluminescence immunoassay kit and detection method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210716 |